Universitätsklinikum Halle (Saale)
Welcome,         Profile    Billing    Logout  
 48 Trials 
64 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Herth, Felix JF
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP
Active, not recruiting
3
1667
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
10/25
10/25
NCT06317285: A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Recruiting
2
150
Europe, Canada, US, RoW
GSK3915393, Placebo
GlaxoSmithKline
Idiopathic Pulmonary Fibrosis
03/26
03/26
NCT03685526: Cinenses Lung Volume Reduction Reverser System First-in-man Study Treating Patients With Severe Emphysema

Active, not recruiting
N/A
15
Europe
Cinenses Lung Volume Reduction Reverser System
Lifetech Scientific (Shenzhen) Co., Ltd.
Emphysema
10/21
08/22
CONVERT, NCT04559464: Fissure Closure With the AeriSeal System for ing Collateral Ventilation Status

Completed
N/A
102
Europe, RoW
AeriSeal, Zephyr Valves, Bronchoscopic Lung Volume Reduction (BLVR), Zephyr System
Pulmonx Corporation
Emphysema, COPD, Severe Emphysema
10/23
10/24
NCT06035120: An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients with Severe Emphysema

Recruiting
N/A
200
Europe, US, RoW
AeriSeal System
Pulmonx Corporation
Emphysema, Pulmonary, Emphysema or COPD
06/27
03/28
IAB-1, NCT05087641: A Multicenter, Prospective Trial of the IAB in Adults Suffering From COPD/Emphysema

Active, not recruiting
N/A
20
Europe, RoW
IAB System
Pulmair Medical, Inc.
Emphysema, Pulmonary Disease, Chronic Obstructive
04/24
01/27
RheSolve, NCT04677465: Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis

Active, not recruiting
N/A
270
Europe, US
RheOx Bronchial Rheoplasty, Sham Procedure
Gala Therapeutics, Inc.
Chronic Bronchitis
05/24
10/25
AIRFLOW-3, NCT03639051: Evaluation of the Safety and Efficacy of TLD in Patients with COPD

Active, not recruiting
N/A
464
Europe, US
Targeted Lung Denervation (TLD), TLD, TLD Therapy, Optimal Medical Care
Nuvaira, Inc.
COPD
10/24
09/28
NCT04182841: RheOx Registry Study in Europe

Recruiting
N/A
100
Europe
RheOx
Gala Therapeutics, Inc.
Chronic Bronchitis, COPD
12/24
12/25
NCT03318406: Post-Market BTVA Registry

Recruiting
N/A
300
Europe
Bronchoscopic Thermal Vapor Ablation, BTVA, InterVapor
Uptake Medical Technology, Inc.
Emphysema or COPD
12/27
12/30
Michl, Patrick
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Active, not recruiting
2
352
Europe, Canada, US
tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin
Seagen Inc., Genmab, Merck Sharp & Dohme LLC
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
02/26
11/26
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)

Completed
N/A
400
Europe
FoundationOne®CDx and FoundationOne®Liquid
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
08/24
08/24
Büchner-Steudel, Petra
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)

Completed
N/A
400
Europe
FoundationOne®CDx and FoundationOne®Liquid
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
08/24
08/24
Braun, Thorsten
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
NCT03250338 / 2017-001600-29: Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Recruiting
3
322
Europe, Canada, US
Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF
Arog Pharmaceuticals, Inc.
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
10/24
10/24
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
10/25
06/33
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Checkmark Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Hourglass Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
Hourglass Sep 2021 - Dec 2021 : Submission for r/r DLBCL
Active, not recruiting
3
440
Europe, Canada, Japan, US, RoW
Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin
ADC Therapeutics S.A., ADC Therapeutics SA
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
06/25
06/28
VITALIZE, NCT04920617 / 2021-003712-27: DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting
2b
102
Europe, Canada, US, RoW
DPX-Survivac, maveropepimut-S, Pembrolizumab, MK-3475, Keytruda, CPA, Intermittent, low-dose cyclophosphamide, Procytox, Cytoxan
ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
10/24
04/25
SELECT-AML-1, NCT04905407 / 2021-003910-38: Tamibarotene Plus Venetoclax/Azacitidine in Participants with Newly Diagnosed AML

Active, not recruiting
2
95
Europe, US
Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza
Syros Pharmaceuticals, Syros Pharmaceuticals, Inc.
Acute Myeloid Leukemia
04/28
04/28
IFM 2021-01, NCT05572229: Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma

Recruiting
2
74
Europe
Teclistamab, JNJ-64007957, Daratumumab, Lenalidomide
University Hospital, Lille, Janssen Pharmaceutica N.V., Belgium
Multiple Myeloma
05/25
09/30
AVENHIR, NCT05768711: Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia

Recruiting
2
44
Europe
Venetoclax, ABT-199
Groupe Francophone des Myelodysplasies, AbbVie
Chronic Myeloid Leukemia
02/26
10/28
ALFA2101, NCT05260528: CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

Recruiting
2
210
Europe
Cytarabine and Idarubicin, CPX-315
Centre Hospitalier Universitaire de Nice, Jazz Pharmaceuticals, Acute Leukemia French Association
Acute Myeloid Leukemia
10/27
10/27
NCT05782127: Oral Azacitidine Combined with Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes

Recruiting
1/2
36
Europe
Onureg + Venetoclax, CC-486 + ABT-199
Groupe Francophone des Myelodysplasies, Bristol-Myers Squibb, AbbVie
Untreated Myelodysplastic Syndrome
11/25
11/28
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Active, not recruiting
1/2
122
Europe, US, RoW
Vodobatinib (K0706) capsules
Sun Pharma Advanced Research Company Limited
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
08/26
08/26
NCT05181735: Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

Recruiting
1/2
150
Europe
Luspatercept Injection [Reblozyl], ACE-536, Eprex, Epoietin alfa
Groupe Francophone des Myelodysplasies, Celgene
MDS, Myelodysplastic Syndromes
05/27
11/27
Renzis, Benoit de
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
Kiani, Alexander
INTEGRATEIIb, NCT04879368 / 2020-004617-12: RegoNivo vs Standard of Care Chemotherapy in AGOC

Active, not recruiting
3
450
Europe, Japan, US, RoW
Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf
Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health
Gastro-Oesophageal Cancer
06/25
06/26
NCT03530267: Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer

Completed
2
124
Europe
Aflibercept + mLV5FU2, mFOLFOX7
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, STABIL - Statistische und Biometrische Lösungen, Trium Analysis Online GmbH, Sanofi
Colorectal Cancer
02/24
02/24
KER050-MD-201, NCT04419649 / 2021-001838-19: A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Hourglass Dec 2024 - Dec 2024 : Additional data for very low, low, or intermediate risk myelodysplastic syndrome
Hourglass Jul 2023 - Dec 2023 : Enrollment completion of transfusion dependent cohorts of trial for low, or intermediate risk MDS
Recruiting
2
140
Europe, US, RoW
KER-050
Keros Therapeutics, Inc., Keros Therapeutics, Inc.
Myelodysplastic Syndromes, Cytopenia
06/25
11/25
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology

Completed
N/A
499
Europe
iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG
Advanced Solid Tumors or Hematologic Malignancies
06/23
06/23
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)

Completed
N/A
400
Europe
FoundationOne®CDx and FoundationOne®Liquid
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
08/24
08/24
Krug, Sebastian
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)

Completed
N/A
400
Europe
FoundationOne®CDx and FoundationOne®Liquid
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
08/24
08/24
Al-Ali, Haifa Kathrin
ROP-ET, NCT06514807: A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients

Active, not recruiting
3
117
Europe, RoW
Ropeginterferon alfa-2b (BESREMi®)
AOP Orphan Pharmaceuticals AG
Essential Thrombocythaemia
03/28
03/28
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
NCT03250338 / 2017-001600-29: Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Recruiting
3
322
Europe, Canada, US
Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF
Arog Pharmaceuticals, Inc.
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
10/24
10/24
ERNEST-3, NCT06533813: Clinical Epidemiology in Contemporary Patients With Myelofibrosis.

Recruiting
N/A
617
Europe, RoW
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS, GlaxoSmithKline
Myelofibrosis
12/25
12/28
Eisenmann, Stephan
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Active, not recruiting
3
758
Europe, Canada, Japan, US, RoW
Cobolimab, Dostarlimab, Docetaxel
GlaxoSmithKline
Lung Cancer, Non-Small Cell
04/25
10/25
CIV-19-07-029227, NCT05153122: A Feasibility Study of Wearable Device in Assessing Respiratory Condition Change of Patients With Exacerbation of COPD

Completed
N/A
15
Europe, RoW
SenseGuard
NanoVation
COPD Exacerbation
05/22
05/23
NCT06035120: An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients with Severe Emphysema

Recruiting
N/A
200
Europe, US, RoW
AeriSeal System
Pulmonx Corporation
Emphysema, Pulmonary, Emphysema or COPD
06/27
03/28
NCT03318406: Post-Market BTVA Registry

Recruiting
N/A
300
Europe
Bronchoscopic Thermal Vapor Ablation, BTVA, InterVapor
Uptake Medical Technology, Inc.
Emphysema or COPD
12/27
12/30
Walldorf, Jens
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Active, not recruiting
3
160
Europe, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
08/24
09/25
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
Jobe, Robert L
CorCinch-HF, NCT04331769: Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF): the CORCINCH-HF Study

Recruiting
N/A
400
Europe, US, RoW
AccuCinch Ventricular Restoration System, Guideline-Directed Medical Therapy
Ancora Heart, Inc.
Heart Failure with Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
12/26
12/30
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

Recruiting
N/A
1252
Europe, Canada, US
Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
Abiomed Inc.
Left Ventricular Dysfunction, Coronary Artery Disease
03/26
10/27
Cohen, Jose Enrique
FIRST, NCT04034810: Safety and Efficacy of Silk Vista and Silk Vista Baby Flow Diverter for Intracranial Aneurysm Treatment

Active, not recruiting
N/A
234
Europe, RoW
Intracranial aneurysm treated with Silk vista and silk vista baby
Balt Extrusion
Intracranial Aneurysm
03/23
11/27
COATING, NCT04870047: Coating to Optimize Aneurysm Treatment In The New Flow Diverter Generation

Recruiting
N/A
170
Europe, RoW
Endovascular treatment of unruptured aneurysms with p64 MW HPC Flow Modulation Device
Phenox GmbH
Intracranial Aneurysm
12/24
12/24
Lechardeur, Jessica
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Jan 2024 - Dec 2024: Approval for myelofibrosis
Hourglass Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Feb 2024 - Feb 2024: Exclusivity expiry in US
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
Edouart, Geoffrey
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
VITALIZE, NCT04920617 / 2021-003712-27: DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting
2b
102
Europe, Canada, US, RoW
DPX-Survivac, maveropepimut-S, Pembrolizumab, MK-3475, Keytruda, CPA, Intermittent, low-dose cyclophosphamide, Procytox, Cytoxan
ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
10/24
04/25
SELECT-AML-1, NCT04905407 / 2021-003910-38: Tamibarotene Plus Venetoclax/Azacitidine in Participants with Newly Diagnosed AML

Active, not recruiting
2
95
Europe, US
Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza
Syros Pharmaceuticals, Syros Pharmaceuticals, Inc.
Acute Myeloid Leukemia
04/28
04/28
Dierks, Christine
VINCENT, NCT05904106 / 2021-003248-26: Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML

Recruiting
2
146
Europe
Venetoclax plus Azacitidine, standard of care chemotherapy plus gemtuzumab ozogamicin
Technische Universität Dresden, University Hospital Heidelberg, AbbVie
Acute Myeloid Leukemia
09/28
09/28
MOSAIC, NCT04385290 / 2019-003863-23: Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia

Recruiting
1/2
214
Europe
MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO, Rydapt, Mylotarg, MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO, MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO, MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin, MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin
Technische Universität Dresden, Novartis Pharmaceuticals, Pfizer
Acute Myeloid Leukemia
04/27
04/28
Gabor, Szabo
AKITA, NCT05126303: Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery

Terminated
2
177
Europe, Canada, US, RoW
RMC-035, ROSgard, Placebo
Guard Therapeutics AB
Acute Kidney Injury
04/23
07/23
POINTER, NCT06475274: A Phase 2b Dose Finding Study of RMC-035 in Participants Undergoing Open-chest Cardiac Surgery

Recruiting
2
161
Europe, Canada
RMC-035, Placebo
Guard Therapeutics AB
Kidney Injury Following Open-Chest Cardiac Surgery
10/25
10/25
Böhm, Johannes
AKITA, NCT05126303: Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery

Terminated
2
177
Europe, Canada, US, RoW
RMC-035, ROSgard, Placebo
Guard Therapeutics AB
Acute Kidney Injury
04/23
07/23
POINTER, NCT06475274: A Phase 2b Dose Finding Study of RMC-035 in Participants Undergoing Open-chest Cardiac Surgery

Recruiting
2
161
Europe, Canada
RMC-035, Placebo
Guard Therapeutics AB
Kidney Injury Following Open-Chest Cardiac Surgery
10/25
10/25
Schweitzer, Nora
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)

Completed
N/A
400
Europe
FoundationOne®CDx and FoundationOne®Liquid
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
08/24
08/24
Damm, Marko
NCT04511455: Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment

Completed
2
22
Europe
Cabozantinib
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Ipsen
Hepatocellular Carcinoma Non-resectable, Metastatic Hepatocellular Carcinoma
12/24
12/24
Moritz, Ute
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)

Completed
N/A
400
Europe
FoundationOne®CDx and FoundationOne®Liquid
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
08/24
08/24
Schob, Stefan
COATING, NCT04870047: Coating to Optimize Aneurysm Treatment In The New Flow Diverter Generation

Recruiting
N/A
170
Europe, RoW
Endovascular treatment of unruptured aneurysms with p64 MW HPC Flow Modulation Device
Phenox GmbH
Intracranial Aneurysm
12/24
12/24
REheal, NCT05543447: DERIVO® 2heal® Study: Clinical Safety and Efficacy of the DERIVO® 2heal® Embolisation Device

Recruiting
N/A
158
Europe
Flow Diverter Treatment with DERIVO 2 Heal Embolisation Device
Acandis GmbH
Intracranial Aneurysm, Flow Diverter
12/25
12/26
NCT04927156: Safety, Performance and Usability of BALT Medical Devices: The EVIDENCE Post Marketing Clinical Follow-up Platform

Recruiting
N/A
10000
Europe
BALT medical devices
Balt Extrusion
Intracranial Aneurysm, Brain Arterial Disease, Acute Ischemic Stroke, Peripheral Vascular Diseases, AVM - Cerebral Arteriovenous Malformation, AVM
06/41
10/41
Stankowski, Tomasz
NCT06570902: Prospective WCD Post CABG Registry (CABG Registry)

Recruiting
N/A
910
Europe
WCD
Zoll Medical Corporation
Cardiomyopathy Ischemic, Cardiomyopathies, Cardiovascular Diseases, Heart Disease, Ischemic
11/29
05/30

Download Options